Chair
Daniel G. Haller, MD
University of Pennsylvania
Abramson Cancer Center
Philadelphia, Pennsylvania

Faculty
John Marshall, MD
Georgetown University
Lombardi Comprehensive Cancer Center
Washington, DC

Edith Mitchell, MD, FACP
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with metastatic colorectal cancer.

After successful completion of this educational activity, participants should be able to:

• Evaluate recently reported clinical data surrounding the use of novel antiangiogenic strategies in the management of metastatic colorectal cancer (CRC)
  
  
• Identify novel nonantiangiogenic molecularly targeted agents, and discuss their clinical development status

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.